# 24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients

> **NCT03702829** · PHASE2 · TERMINATED · sponsor: **Brigham and Women's Hospital** · enrollment: 31 (actual)

## Conditions studied

- Amyloidosis

## Interventions

- **DRUG:** Inotersen

## Key facts

- **NCT ID:** NCT03702829
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-02-28
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-01-15
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** recruitment of new patients not possible during Covid 19 epidemic
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03702829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03702829, "24 Month Open Label Study of the Tolerability and Efficacy of Inotersen in TTR Amyloid Cardiomyopathy Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03702829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*